1. Indicators of the Nations Health: Mortality Statistics: Office for National Statistics, 1997.

2. Parkin DM, Muir CS. Cancer Incidence in Five Continents. IARC Scientific Publications (Lyon) 1992(120):45-173.

3. Cummings JH, Bingham SA. Diet and the prevention of cancer. BMJ 1998;317(7173):1636-40.

4. Doll R. The lessons of life: keynote address to the nutrition and cancer conference. Cancer Research 1992;52(7 Suppl):2024s-2029s.

5. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54(4):594-606.

6. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993;55(6):891-903.

7. OPCS. 1995 mortality statistics by cause: England and Wales 1992: London HMSU, 1995.

8. Ponz de Leon M, Antonioli A, Ascari A, Zanghieri G, Sacchetti C. Incidence and familial occurrence of colorectal cancer and polyps in a health-care district of northern Italy. Cancer 1987;60(11):2848-59.

9. Boyle P, Langman JS. ABC of colorectal cancer: Epidemiology. Bmj 2000;321(7264):805-8.

10. Atkin WS, Cuzick J, Northover JM, Whynes DK. Prevention of colorectal cancer by once-only sigmoidoscopy [see comments]. Lancet 1993;341(8847):736-40.

11. Welin S. The Rates and Patterns of Growth of 375 Tumours of the Large Intestine  and Rectum Observed Serially by Double Contrast Barium Enema Study. American Journal of Roentology Radium Therapy and Nuclear Medicine 1963;90:673-687.

12. Knoernschild H. Growth Rate and Malignant Potential of Colonic Polyps:early results. Surgical Forum 1963;14:137-138.

13. Stryker SJ, Wolff BG, Culp CE, Libbe SD, Ilstrup DM, MacCarty RL. Natural history of untreated colonic polyps. Gastroenterology 1987;93(5):1009-13.

14. Jass JR. Do all colorectal carcinomas arise in preexisting adenomas? World Journal of Surgery 1989;13(1):45-51.

15. Clark JC, Collan Y, Eide TJ, et al. Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. International Journal of Cancer 1985;36(2):179-86.

16. Morson BC. Genesis of colorectal cancer. Clinics in Gastroenterology 1976;5(3):505-25.

17. Eide TJ. Risk of colorectal cancer in adenoma-bearing individuals within a defined population. Int J Cancer 1986;38(2):173-6.

18. Foulds L. The natural history of cancer. Journal of Chronic Diseases 1958;8:2-37.

19. Fearon ER, Hamilton SR, Vogelstein B. Clonal analysis of human colorectal tumors. Science 1987;238(4824):193-7.

20. Ponder BA, Wilkinson MM. Direct examination of the clonality of carcinogen-induced colonic epithelial dysplasia in chimeric mice. J Natl Cancer Inst 1986;77(4):967-76.

21. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61(5):759-67.

22. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. New England Journal of Medicine 1988;319(9):525-32.

23. Cho KR, Vogelstein B. Genetic alterations in the adenoma--carcinoma sequence. Cancer 1992;70(6 Suppl):1727-31.

24. Lipkin M. Biomarkers of increased susceptibility of gastrointestinal cancer: new application to studies of cancer prevention in human subjects. Cancer Research 1988;48:235-245.

25. Olschwang S, Weiffenbach B, Laurent-Puig P, et al. Genetic characterization of the APC locus involved in familial adenomatous polyposis. Gastroenterology 1991;101(1):154-60.

26. Rubinfeld B, Souza B, Albert I, et al. Association of the APC gene product with beta-catenin. Science 1993;262(5140):1731-4.

27. Prescott SM, White RL. Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. Cell 1996;87(5):783-6.

28. Rustgi AK. Cyclooxygenase-2: the future is now [news]. Nature Medicine 1998;4(7):773-4.

29. Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985(228):187-190.

30. Schmid M, Haaf T, Grunert D. 5-Azacytidine-induced undercondensations in human chromosomes. Human Genetics 1984;67:257-263.

31. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987;327(6120):293-7.

32. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987;327(6120):298-303.

33. Reichmann A, Martin P, Levin B. Chromosomal banding patterns in human large bowel cancer. Int J Cancer 1981;28(4):431-40.

34. Muleris M, Salmon RJ, Zafrani B, Girodet J, Dutrillaux B. Consistent deficiencies of chromosome 18 and of the short arm of chromosome 17 in eleven cases of human large bowel cancer: a possible recessive determinism. Ann Genet 1985;28(4):206-13.

35. Hedrick L, Cho KR, Fearon ER, Wu TC, Kinzler KW, Vogelstein B. The DCC gene product in cellular differentiation and colorectal tumorigenesis. Genes & Development 1994;8(10):1174-83.

36. Lairmore TC, Norton JA. Advances in molecular genetics. Am J Surg 1997;173(1):37-41; discussion 42-3.

37. Velcich A, Corner G, Palumbo L, Augenlicht L. Altered phenotype of HT29 colonic adenocarcinoma cells following expression of the DCC gene. Oncogene 1999;18(16):2599-606.

38. Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989;244(4901):217-21.

39. Delattre O, Olschwang S, Law DJ, et al. Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 1989;2(8659):353-6.

40. Kikuchi-Yanoshita R, Konishi M, Ito S, et al. Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res 1992;52(14):3965-71.

41. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342(6250):705-8.

42. Stephenson BM, Finan PJ, Gascoyne J, Garbett F, Murday VA, Bishop DT. Frequency of familial colorectal cancer. British Journal of Surgery 1991;78(10):1162-6.

43. Potter JD. Colorectal cancer: molecules and populations. Journal of the National Cancer Institute 1999;91(11):916-32.

44. Leppert M, Dobbs M, Scambler P, et al. The gene for familial polyposis coli maps to the long arm of chromosome 5. Science 1987;238(4832):1411-3.

45. Bodmer WF, Bailey CJ, Bodmer J, et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 1987;328(6131):614-6.

46. Gardner EJ, Richards RC. Multiple cutaneous and subcutaneous lesions occurring simultaneously with hereditary polyposis and osteomatosis. American Journal of Human Genetics 1953;5:139-47.

47. Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995;332(13):839-47.

48. National Centre for Biotechnology Information Website, 2001.

49. Spirio L, Olschwang S, Groden J, et al. Alleles of the APC gene: an attenuated form of familial polyposis. Cell 1993;75(5):951-7.

50. Gayther SA, Wells D, SenGupta SB, et al. Regionally clustered APC mutations are associated with a severe phenotype and occur at a high frequency in new mutation cases of adenomatous polyposis coli. Hum Mol Genet 1994;3(1):53-6.

51. Giardiello FM, Petersen GM, Piantadosi S, et al. APC gene mutations and extraintestinal phenotype of familial adenomatous polyposis. Gut 1997;40(4):521-5.

52. Evans DG, Walsh S, Jeacock J, et al. Incidence of hereditary non-polyposis colorectal cancer in a population- based study of 1137 consecutive cases of colorectal cancer. Br J Surg 1997;84(9):1281-5.

53. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991;34(5):424-5.

54. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997;89(23):1758-62.

55. Umar A, Kunkel TA. DNA-replication fidelity, mismatch repair and genome instability in cancer cells. Eur J Biochem 1996;238(2):297-307.

56. Peltomaki P, de la Chapelle A. Mutations predisposing to hereditary nonpolyposis colorectal cancer. Adv Cancer Res 1997;71:93-119.

57. Malkhosyan S, Rampino N, Yamamoto H, Perucho M. Frameshift mutator mutations. Nature 1996;382(6591):499-500.

58. St John DJ, McDermott FT, Hopper JL, Debney EA, Johnson WR, Hughes ES. Cancer risk in relatives of patients with common colorectal cancer. Ann Intern Med 1993;118(10):785-90.

59. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer [see comments]. New England Journal of Medicine 1994;331(25):1669-74.

60. Bartsch H, Hietanen E. The role of individual susceptibility in cancer burden related to environmental exposure. Environ Health Perspect 1996;104 Suppl 3:569-77.

61. Crespi CL, Penman BW, Gelboin HV, Gonzalez FJ. A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis 1991;12(7):1197-201.

62. Cotton SC, Sharp L, Little J, Brockton N. Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol 2000;151(1):7-32.

63. Zhong S, Wyllie AH, Barnes D, Wolf CR, Spurr NK. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 1993;14(9):1821-4.

64. Probst-Hensch NM, Haile RW, Ingles SA, et al. Acetylation polymorphism and prevalence of colorectal adenomas. Cancer Research 1995;55(10):2017-20.

65. Inoue H, Kiyohara C, Marugame T, et al. Cigarette smoking, CYP1A1 MspI and GSTM1 genotypes, and colorectal adenomas. Cancer Research 2000;60(14):3749-52.

66. Lin HJ, Probst-Hensch NM, Ingles SA, et al. Glutathione transferase (GSTM1) null genotype, smoking, and prevalence of colorectal adenomas. Cancer Res 1995;55(6):1224-6.

67. Inoue H, Kiyohara C, Shinomiya S, et al. Glutathione S-transferase polymorphisms and risk of colorectal adenomas. Cancer Lett 2001;163(2):201-6.

68. Katoh T, Nagata N, Kuroda Y, et al. Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) genetic polymorphism and susceptibility to gastric and colorectal adenocarcinoma. Carcinogenesis 1996;17(9):1855-9.

69. Szarka CE, Pfeiffer GR, Hum ST, et al. Glutathione S-transferase activity and glutathione S-transferase mu expression in subjects with risk for colorectal cancer. Cancer Res 1995;55(13):2789-93.

70. Abdel-Rahman SZ, Soliman AS, Bondy ML, et al. Polymorphism of glutathione S-transferase loci GSTM1 and GSTT1 and susceptibility to colorectal cancer in Egypt. Cancer Lett 1999;142(1):97-104.

71. Chenevix-Trench G, Young J, Coggan M, Board P. Glutathione S-transferase M1 and T1 polymorphisms: susceptibility to colon cancer and age of onset. Carcinogenesis 1995;16(7):1655-7.

72. Gertig DM, Stampfer M, Haiman C, Hennekens CH, Kelsey K, Hunter DJ. Glutathione S-transferase GSTM1 and GSTT1 polymorphisms and colorectal cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev 1998;7(11):1001-5.

73. Deakin M, Elder J, Hendrickse C, et al. Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis 1996;17(4):881-4.

74. Sivaraman L, Leatham MP, Yee J, Wilkens LR, Lau AF, Le Marchand L. CYP1A1 genetic polymorphisms and in situ colorectal cancer. Cancer Res 1994;54(14):3692-5.

75. Kiss I, Sandor J, Pajkos G, Bogner B, Hegedus G, Ember I. Colorectal cancer risk in relation to genetic polymorphism of cytochrome P450 1A1, 2E1, and glutathione-S-transferase M1 enzymes. Anticancer Res 2000;20(1B):519-22.

76. Lang NP, Butler MA, Massengill J, et al. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiology, Biomarkers & Prevention 1994;3(8):675-82.

77. Hakkak R, Korourian S, Ronis MJ, Ingelman-Sundberg M, Badger TM. Effects of diet and ethanol on the expression and localization of cytochromes P450 2E1 and P450 2C7 in the colon of male rats. Biochem Pharmacol 1996;51(1):61-9.

78. Nomiyama T, Nakashima H, Sano Y, et al. Does the polymorphism of cytochrome P-450 2E1 affect the metabolism of N,N-dimethylformamide? Comparison of the half-lives of urinary N- methylformamide. Arch Toxicol 2001;74(12):755-9.

79. Omiecinski CJ, Aicher L, Holubkov R, Checkoway H. Human peripheral lymphocytes as indicators of microsomal epoxide hydrolase activity in liver and lung. Pharmacogenetics 1993;3(3):150-8.

80. Harrison DJ, Hubbard AL, MacMillan J, Wyllie AH, Smith CA. Microsomal epoxide hydrolase gene polymorphism and susceptibility to colon cancer. Br J Cancer 1999;79(1):168-71.

81. Cortessis V, Siegmund K, Chen Q, et al. A case-control study of microsomal epoxide hydrolase, smoking, meat consumption, glutathione S-transferase M3, and risk of colorectal adenomas. Cancer Res 2001;61(6):2381-5.

82. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001;22(4):195-201.

83. Chen J, Giovannucci E, Kelsey K, et al. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996;56(21):4862-4.

84. Ma J, Stampfer MJ, Giovannucci E, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Research 1997;57(6):1098-102.

85. Ulrich CM, Kampman E, Bigler J, et al. Colorectal adenomas and the C677T MTHFR polymorphism: evidence for gene- environment interaction? Cancer Epidemiol Biomarkers Prev 1999;8(8):659-68.

86. Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Speizer FE. Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women [see comments]. New England Journal of Medicine 1990;323(24):1664-72.

87. Willett W. The search for the causes of breast and colon cancer. Nature 1989;338(6214):389-94.

88. Slattery ML, Caan BJ, Potter JD, et al. Dietary energy sources and colon cancer risk. American Journal of Epidemiology 1997;145(3):199-210.

89. Burkitt DP. Epidemiology of cancer of the colon and rectum. Cancer 1971;28(1):3-13.

90. Giovannucci E, Stampfer MJ, Colditz G, Rimm EB, Willett WC. Relationship of diet to risk of colorectal adenoma in men [see comments]. Journal of the National Cancer Institute 1992;84(2):91-8.

91. Witte JS, Longnecker MP, Bird CL, Lee ER, Frankl HD, Haile RW. Relation of vegetable, fruit, and grain consumption to colorectal adenomatous polyps [see comments]. American Journal of Epidemiology 1996;144(11):1015-25.

92. Bingham SA. Mechanisms and experimental and epidemiological evidence relating dietary fibre (non-starch polysaccharides) and starch to protection against large bowel cancer. Proceedings of the Nutrition Society 1990;49(2):153-71.

93. Potter JD, McMichael AJ. Diet and cancer of the colon and rectum: a case-control study. Journal of the National Cancer Institute 1986;76(4):557-69.

94. Garland C, Shekelle RB, Barrett-Connor E, Criqui MH, Rossof AH, Paul O. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet 1985;1(8424):307-9.

95. Giovannucci E, Rimm EB, Ascherio A, Stampfer MJ, Colditz GA, Willett WC. Alcohol, low-methionine--low-folate diets, and risk of colon cancer in men [see comments]. Journal of the National Cancer Institute 1995;87(4):265-73.

96. Tuyns AJ. A case-control study on colorectal cancer in Belgium. Preliminary results. Sozial- und Praventivmedizin 1986;31(2):81-2.

97. Giovannucci E, Stampfer MJ, Colditz GA, et al. Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. Annals of Internal Medicine 1998;129(7):517-24.

98. Tuyns AJ, Haelterman M, Kaaks R. Colorectal cancer and the intake of nutrients: oligosaccharides are a risk factor, fats are not. A case-control study in Belgium. Nutr Cancer 1987;10(4):181-96.

99. Jansson B. Geographic mappings of colorectal cancer rates: a retrospect of studies, 1974-1984. Cancer Detect Prev 1985;8(3):341-8.

100. Giovannucci E, Stampfer MJ, Colditz GA, et al. Folate, methionine, and alcohol intake and risk of colorectal adenoma [see comments]. Journal of the National Cancer Institute 1993;85(11):875-84.

101. Franceschi S, La Vecchia C, Russo A, et al. Macronutrient intake and risk of colorectal cancer in Italy. International Journal of Cancer 1998;76(3):321-4.

102. Gerhardsson de Verdier M, Hagman U, Steineck G, Rieger A, Norell SE. Diet, body mass and colorectal cancer: a case-referent study in Stockholm. International Journal of Cancer 1990;46(5):832-8.

103. Caygill CP, Charlett A, Hill MJ. Fat, fish, fish oil and cancer. British Journal of Cancer 1996;74(1):159-64.

104. Prentice RL, Sheppard L. Dietary fat and cancer: consistency of the epidemiologic data, and disease prevention that may follow from a practical reduction in fat consumption. Cancer Causes Control 1990;1(1):81-97; discussion 99-109.

105. Graham S, Marshall J, Haughey B, et al. Dietary epidemiology of cancer of the colon in western New York. American Journal of Epidemiology 1988;128(3):490-503.

106. Lyon JL, Mahoney AW, West DW, et al. Energy intake: its relationship to colon cancer risk. Journal of the National Cancer Institute 1987;78(5):853-61.

107. Slattery ML, Schumacher MC, Smith KR, West DW, Abd-Elghany N. Physical activity, diet, and risk of colon cancer in Utah [see comments]. American Journal of Epidemiology 1988;128(5):989-99.

108. Jain M, Cook GM, Davis FG, Grace MG, Howe GR, Miller AB. A case-control study of diet and colo-rectal cancer. Int J Cancer 1980;26(6):757-68.

109. Kune S, Kune GA, Watson LF. Case-control study of dietary etiological factors: the Melbourne Colorectal Cancer Study. Nutr Cancer 1987;9(1):21-42.

110. Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, Day NE. Colorectal cancer and diet in an Asian population--a case-control study among Singapore Chinese. International Journal of Cancer 1989;43(6):1007-16.

111. Hsing AW, McLaughlin JK, Chow WH, et al. Risk factors for colorectal cancer in a prospective study among U.S. white men. International Journal of Cancer 1998;77(4):549-53.

112. Kono S, Imanishi K, Shinchi K, Yanai F. Relationship of diet to small and large adenomas of the sigmoid colon. Japanese Journal of Cancer Research 1993;84(1):13-9.

113. Sinha R, Chow WH, Kulldorff M, et al. Well-done, grilled red meat increases the risk of colorectal adenomas. Cancer Res 1999;59(17):4320-4.

114. Breuer-Katschinski B, Nemes K, Marr A, et al. Colorectal adenomas and diet: a case-control study. Colorectal Adenoma Study Group. Dig Dis Sci 2001;46(1):86-95.

115. Sinha R, Kulldorff M, Chow WH, Denobile J, Rothman N. Dietary intake of heterocyclic amines, meat-derived mutagenic activity, and risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2001;10(5):559-62.

116. Yoon H, Benamouzig R, Little J, Francois-Collange M, Tome D. Systematic review of epidemiological studies on meat, dairy products and egg consumption and risk of colorectal adenomas. Eur J Cancer Prev 2000;9(3):151-64.

117. Sugimura T. Carcinogenicity of mutagenic heterocyclic amines formed during the cooking process. Mutat Res 1985;150(1-2):33-41.

118. Sinha R, Rothman N. Role of well-done, grilled red meat, heterocyclic amines (HCAs) in the etiology of human cancer. Cancer Lett 1999;143(2):189-94.

119. Bingham SA, Pignatelli B, Pollock JR, et al. Does increased endogenous formation of N-nitroso compounds in the human colon explain the association between red meat and colon cancer? Carcinogenesis 1996;17(3):515-23.

120. Schiffman MH, Felton JS. Re: "Fried foods and the risk of colon cancer". Am J Epidemiol 1990;131(2):376-8.

121. Probst-Hensch NM, Sinha R, Longnecker MP, et al. Meat preparation and colorectal adenomas in a large sigmoidoscopy-based case-control study in California (United States). Cancer Causes Control 1997;8(2):175-83.

122. Blot WJ. Alcohol and cancer. Cancer Research 1992;52(7 Suppl):2119s-2123s.

123. Boffetta P, Garfinkel L. Alcohol drinking and mortality among men enrolled in an American Cancer Society prospective study [see comments]. Epidemiology 1990;1(5):342-8.

124. Alcohol Drinking, IARC Monographs on the Evaluation of the Carcinogenic Risk to Humans. Lyon, France: International Agency for Research on Cancer, 1988.

125. Klatsky AL, Armstrong MA, Friedman GD, Hiatt RA. The relations of alcoholic beverage use to colon and rectal cancer. Am J Epidemiol 1988;128(5):1007-15.

126. Bristol JB, Emmett PM, Heaton KW, Williamson RC. Sugar, fat, and the risk of colorectal cancer. Br Med J (Clin Res Ed) 1985;291(6507):1467-70.

127. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Intake of fat, meat, and fiber in relation to risk of colon cancer in men. Cancer Research 1994;54(9):2390-7.

128. Arbman G, Axelson O, Ericsson-Begodzki AB, Fredriksson M, Nilsson E, Sjodahl R. Cereal fiber, calcium, and colorectal cancer. Cancer 1992;69(8):2042-8.

129. Greenwald P, Lanza E, Eddy GA. Dietary fiber in the reduction of colon cancer risk. Journal of the American Dietetic Association 1987;87(9):1178-88.

130. Dwyer J. Dietary fiber and colorectal cancer risk. Nutr Rev 1993;51(5):147-8.

131. Fuchs CS, Giovannucci EL, Colditz GA, et al. Dietary fiber and the risk of colorectal cancer and adenoma in women [see comments]. New England Journal of Medicine 1999;340(3):169-76.

132. Martinez ME, McPherson RS, Annegers JF, Levin B. Association of diet and colorectal adenomatous polyps: dietary fiber, calcium, and total fat. Epidemiology 1996;7(3):264-8.

133. La Vecchia C, Braga C, Negri E, et al. Intake of selected micronutrients and risk of colorectal cancer. International Journal of Cancer 1997;73(4):525-30.

134. Hofstad B, Almendingen K, Vatn M, et al. Growth and recurrence of colorectal polyps: a double-blind 3-year intervention with calcium and antioxidants. Digestion 1998;59(2):148-56.

135. Holt PR, Atillasoy EO, Gilman J, et al. Modulation of abnormal colonic epithelial cell proliferation and differentiation by low-fat dairy foods: a randomized controlled trial [see comments]. Jama 1998;280(12):1074-9.

136. Little J, Logan RF, Hawtin PG, Hardcastle JD, Turner ID. Colorectal adenomas and diet: a case-control study of subjects participating in the Nottingham faecal occult blood screening programme. British Journal of Cancer 1993;67(1):177-84.

137. Ferraroni M, La Vecchia C, D'Avanzo B, Negri E, Franceschi S, Decarli A. Selected micronutrient intake and the risk of colorectal cancer. British Journal of Cancer 1994;70(6):1150-5.

138. Kampman E, Goldbohm RA, van den Brandt PA, van 't Veer P. Fermented dairy products, calcium, and colorectal cancer in The Netherlands Cohort Study. Cancer Research 1994;54(12):3186-90.

139. Cats A, Kleibeuker JH, van der Meer R, et al. Randomized, double-blinded, placebo-controlled intervention study with supplemental calcium in families with hereditary nonpolyposis colorectal cancer. Journal of the National Cancer Institute 1995;87(8):598-603.

140. Boutron MC, Faivre J, Marteau P, Couillault C, Senesse P, Quipourt V. Calcium, phosphorus, vitamin D, dairy products and colorectal carcinogenesis: a French case--control study [see comments]. British Journal of Cancer 1996;74(1):145-51.

141. Schloss I, Kidd MS, Tichelaar HY, Young GO, O'Keefe SJ. Dietary factors associated with a low risk of colon cancer in coloured west coast fishermen. South African Medical Journal 1997;87(2):152-8.

142. Levi F, Pasche C, Lucchini F, La Vecchia C. Selected micronutrients and colorectal cancer. a case-control study from the canton of Vaud, Switzerland. Eur J Cancer 2000;36(16):2115-9.

143. Breuer-Katschinski B, Nemes K, Marr A, et al. Relation of serum antioxidant vitamins to the risk of colorectal adenoma. Digestion 2001;63(1):43-8.

144. Franceschi S. Nutrients and food groups and large bowel cancer in Europe. Eur J Cancer Prev 1999;8 Suppl 1:S49-52.

145. Enger SM, Longnecker MP, Chen MJ, et al. Dietary intake of specific carotenoids and vitamins A, C, and E, and prevalence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 1996;5(3):147-53.

146. Whelan RL, Horvath KD, Gleason NR, et al. Vitamin and calcium supplement use is associated with decreased adenoma recurrence in patients with a previous history of neoplasia. Dis Colon Rectum 1999;42(2):212-7.

147. Cahill RJ, O'Sullivan KR, Mathias PM, Beattie S, Hamilton H, O'Morain C. Effects of vitamin antioxidant supplementation on cell kinetics of patients with adenomatous polyps. Gut 1993;34(7):963-7.

148. Heilbrun LK, Nomura A, Hankin JH, Stemmermann GN. Diet and colorectal cancer with special reference to fiber intake. International Journal of Cancer 1989;44(1):1-6.

149. Wu AH, Paganini-Hill A, Ross RK, Henderson BE. Alcohol, physical activity and other risk factors for colorectal cancer: a prospective study. British Journal of Cancer 1987;55(6):687-94.

150. Greenberg ER, Baron JA, Tosteson TD, et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group [see comments]. New England Journal of Medicine 1994;331(3):141-7.

151. Cook MG, McNamara P. Effect of dietary vitamin E on dimethylhydrazine-induced colonic tumors in mice. Cancer Res 1980;40(4):1329-31.

152. McKeown-Eyssen G, Holloway C, Jazmaji V, Bright-See E, Dion P, Bruce WR. A randomized trial of vitamins C and E in the prevention of recurrence of colorectal polyps. Cancer Research 1988;48(16):4701-5.

153. Ghadirian P, Lacroix A, Maisonneuve P, et al. Nutritional factors and colon carcinoma: a case-control study involving French Canadians in Montreal, Quebec, Canada. Cancer 1997;80(5):858-64.

154. Mikac-Devic M, Vukelic N, Kljaic K. Serum selenium level in patients with colorectal cancer. Biol Trace Elem Res 1992;33:87-94.

155. Rumi G, Imre I, Sulle C, Sarudi I, Kelemen J, Lassu Z. Selenium in the blood of patients with colorectal cancer and neoplastic polyp. Acta Physiol Hung 1992;80(1-4):275-9.

156. Clark LC, Hixson LJ, Combs GF, Jr., Reid ME, Turnbull BW, Sampliner RE. Plasma selenium concentration predicts the prevalence of colorectal adenomatous polyps. Cancer Epidemiol Biomarkers Prev 1993;2(1):41-6.

157. Russo MW, Murray SC, Wurzelmann JI, Woosley JT, Sandler RS. Plasma selenium levels and the risk of colorectal adenomas. Nutr Cancer 1997;28(2):125-9.

158. Psathakis D, Wedemeyer N, Oevermann E, Krug F, Siegers CP, Bruch HP. Blood selenium and glutathione peroxidase status in patients with colorectal cancer. Dis Colon Rectum 1998;41(3):328-35.

159. Feng Y, Finley JW, Davis CD, Becker WK, Fretland AJ, Hein DW. Dietary selenium reduces the formation of aberrant crypts in rats administered 3,2'-dimethyl-4-aminobiphenyl. Toxicol Appl Pharmacol 1999;157(1):36-42.

160. Wikman H, Thiel S, Jager B, et al. Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. Pharmacogenetics 2001;11(2):157-68.

161. Boutron MC, Faivre J, Dop MC, Quipourt V, Senesse P. Tobacco, alcohol, and colorectal tumors: a multistep process [see comments]. American Journal of Epidemiology 1995;141(11):1038-46.

162. Giovannucci E, Colditz GA, Stampfer MJ, et al. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. women. J Natl Cancer Inst 1994;86(3):192-9.

163. Giovannucci E, Rimm EB, Stampfer MJ, et al. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. men. J Natl Cancer Inst 1994;86(3):183-91.

164. Almendingen K, Hofstad B, Trygg K, Hoff G, Hussain A, Vatn MH. Smoking and colorectal adenomas: a case-control study. Eur J Cancer Prev 2000;9(3):193-203.

165. Terry MB, Neugut AI. Cigarette smoking and the colorectal adenoma-carcinoma sequence: a hypothesis to explain the paradox [see comments]. American Journal of Epidemiology 1998;147(10):903-10.

166. Le Marchand L, Wilkens LR, Kolonel LN, Hankin JH, Lyu LC. Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. Cancer Research 1997;57(21):4787-94.

167. Giovannucci E, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk of colorectal adenoma in women (United States). Cancer Causes Control 1996;7(2):253-63.

168. Levi F, Pasche C, Lucchini F, Tavani A, La Vecchia C. Occupational and leisure-time physical activity and the risk of colorectal cancer. Eur J Cancer Prev 1999;8(6):487-93.

169. Liu F, Kondo T, Toda Y. Brief physical inactivity prolongs colonic transit time in elderly active men. Int J Sports Med 1993;14(8):465-7.

170. Moses FM. The effect of exercise on the gastrointestinal tract. Sports Med 1990;9(3):159-72.

171. McKeown-Eyssen G. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 1994;3(8):687-95.

172. Martinez ME, Heddens D, Earnest DL, et al. Physical activity, body mass index, and prostaglandin E2 levels in rectal mucosa. J Natl Cancer Inst 1999;91(11):950-3.

173. Shike M. Body weight and colon cancer. American Journal of Clinical Nutrition 1996;63(3 Suppl):442S-444S.

174. Degomme Y. Leading purchasing and information source for the international pharmaceutical and nutritional wholesale community: www.centrall.com, 1999.

175. Chen MJ, Longnecker MP, Morgenstern H, Lee ER, Frankl HD, Haile RW. Recent use of hormone replacement therapy and the prevalence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 1998;7(3):227-30.

176. Kampman E, Potter JD, Slattery ML, Caan BJ, Edwards S. Hormone replacement therapy, reproductive history, and colon cancer: a multicenter, case-control study in the United States. Cancer Causes Control 1997;8(2):146-58.

177. Potter JD, Bostick RM, Grandits GA, et al. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. Cancer Epidemiol Biomarkers Prev 1996;5(10):779-84.

178. Fernandez E, La Vecchia C, Franceschi S, et al. Oral contraceptive use and risk of colorectal cancer. Epidemiology 1998;9(3):295-300.

179. Potter JD. Hormones and colon cancer. J Natl Cancer Inst 1995;87(14):1039-40.

180. Weyant MJ, Carothers AM, Mahmoud NN, et al. Reciprocal expression of ERalpha and ERbeta is associated with estrogen- mediated modulation of intestinal tumorigenesis. Cancer Res 2001;61(6):2547-51.

181. Smirnoff P, Liel Y, Gnainsky J, Shany S, Schwartz B. The protective effect of estrogen against chemically induced murine colon carcinogenesis is associated with decreased CpG island methylation and increased mRNA and protein expression of the colonic vitamin D receptor. Oncol Res 1999;11(6):255-64.

182. Kalgutkar AS, Crews BC, Rowlinson SW, Garner C, Seibert K, Marnett LJ. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science 1998;280(5367):1268-70.

183. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women [see comments]. New England Journal of Medicine 1995;333(10):609-14.

184. Rex DK, Cummings OW, Helper DJ, et al. 5-year incidence of adenomas after negative colonoscopy in asymptomatic average-risk persons [see comment]. Gastroenterology 1996;111(5):1178-81.

185. Nugent KP, Spigelman AD, Phillips RK. Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac. Dis Colon Rectum 1996;39(6):659-62.

186. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328(18):1313-6.

187. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101(3):635-9.

188. Smith CA, Smith G, Wolf CR. Genetic polymorphisms in xenobiotic metabolism. Eur J Cancer 1994;13(35):1921-35.

189. Grant DM. Molecular genetics of the N-acetyltransferases. Pharmacogenetics 1993;3(1):45-50.

190. Sinha R, Rothman N, Brown ED, et al. Pan-fried meat containing high levels of heterocyclic aromatic amines but low levels of polycyclic aromatic hydrocarbons induces cytochrome P4501A2 activity in humans. Cancer Res 1994;54(23):6154-9.

191. Matas N, Thygesen P, Stacey M, Risch A, Sim E. Mapping AAC1, AAC2 and AACP, the genes for arylamine N-acetyltransferases, carcinogen metabolising enzymes on human chromosome 8p22, a region frequently deleted in tumours. Cytogenetics & Cell Genetics 1997;77(3-4):290-5.

192. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA & Cell Biology 1990;9(3):193-203.

193. Ebisawa T, Deguchi T. Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases. Biochem Biophys Res Commun 1991;177(3):1252-7.

194. Windmill KF, Gaedigk A, Hall PM, Samaratunga H, Grant DM, McManus ME. Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol Sci 2000;54(1):19-29.

195. Hickman D, Pope J, Patil SD, et al. Expression of arylamine N-acetyltransferase in human intestine. Gut 1998;42(3):402-9.

196. Rodriguez JW, Kirlin WG, Ferguson RJ, et al. Human acetylator genotype: relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol. Archives of Toxicology 1993;67(7):445-52.

197. Debiec-Rychter M, Land SJ, King CM. Histological localization of acetyltransferases in human tissue. Cancer Lett 1999;143(2):99-102.

198. Weber WW, Vatsis KP. Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood. Pharmacogenetics 1993;3(4):209-12.

199. Lin HJ, Probst-Hensch NM, Hughes NC, et al. Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas. Pharmacogenetics 1998;8(3):269-81.

200. Bell DA, Badawi AF, Lang NP, Ilett KF, Kadlubar FF, Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Research 1995;55(22):5226-9.

201. Taylor JA, Umbach DM, Stephens E, et al. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Research 1998;58(16):3603-10.

202. Zheng W, Deitz AC, Campbell DR, et al. N-acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk. Cancer Epidemiology, Biomarkers & Prevention 1999;8(3):233-9.

203. Katoh T, Boissy R, Nagata N, et al. Inherited polymorphism in the N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and susceptibility to gastric and colorectal adenocarcinoma. International Journal of Cancer 2000;85(1):46-9.

204. Katoh T, Kaneko S, Boissy R, Watson M, Ikemura K, Bell DA. A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. Carcinogenesis 1998;19(10):1803-7.

205. Doll MA, Jiang W, Deitz AC, Rustan TD, Hein DW. Identification of a novel allele at the human NAT1 acetyltransferase locus. Biochemical & Biophysical Research Communications 1997;233(3):584-91.

206. de Leon JH, Vatsis KP, Weber WW. Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1. Molecular Pharmacology 2000;58(2):288-99.

207. Bruhn C, Brockmoller J, Cascorbi I, Roots I, Borchert HH. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochemical Pharmacology 1999;58(11):1759-64.

208. Grant DM, Hughes NC, Janezic SA, et al. Human acetyltransferase polymorphisms. Mutation Research 1997;376(1-2):61-70.

209. Hughes NC, Janezic SA, McQueen KL, et al. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. Pharmacogenetics 1998;8(1):55-66.

210. Bell DA, Stephens EA, Castranio T, et al. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Research 1995;55(16):3537-42.

211. Chen J, Stampfer MJ, Hough HL, et al. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Research 1998;58(15):3307-11.

212. Lee E, Huang Y, Zhao B, Seow-Choen F, Balakrishnan A, Chan SH. Genetic polymorphism of conjugating enzymes and cancer risk: GSTM1, GSTT1, NAT1 and NAT2. Journal of Toxicological Sciences 1998;23(Suppl 2):140-2.

213. Hubbard AL, Moyes C, Wyllie AH, Smith CA, Harrison DJ. N-acetyl transferase 1: two polymorphisms in coding sequence identified in colorectal cancer patients. British Journal of Cancer 1998;77(6):913-6.

214. Probst-Hensch NM, Haile RW, Li DS, et al. Lack of association between the polyadenylation polymorphism in the NAT1 (acetyltransferase 1) gene and colorectal adenomas. Carcinogenesis 1996;17(10):2125-9.

215. Payton MA, Sim E. Genotyping human arylamine N-acetyltransferase type 1 (NAT1): the identification of two novel allelic variants. Biochemical Pharmacology 1998;55(3):361-6.

216. Rothman N, Garcia-Closas M, Stewart WT, Lubin J. Chapter 9. The impact of misclassification in case-control studies of gene-environment interactions. IARC Sci Publ 1999;148:89-96.

217. Rothman N, Stewart WF, Caporaso NE, Hayes RB. Misclassification of genetic susceptibility biomarkers: implications for case-control studies and cross-population comparisons. Cancer Epidemiol Biomarkers Prev 1993;2(4):299-303.

218. Smith CA, Wadelius M, Gough AC, Harrison DJ, Wolf CR, Rane A. A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. Journal of Medical Genetics 1997;34(9):758-60.

219. Le Marchand L, Sivaraman L, Franke AA, et al. Predictors of N-acetyltransferase activity: should caffeine phenotyping and NAT2 genotyping be used interchangeably in epidemiological studies? Cancer Epidemiology, Biomarkers & Prevention 1996;5(6):449-55.

220. Cribb AE, Isbrucker R, Levatte T, Tsui B, Gillespie CT, Renton KW. Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity. Pharmacogenetics 1994;4(3):166-70.

221. Butler MA, Lang NP, Young JF, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992;2(3):116-27.

222. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proceedings of the National Academy of Sciences of the United States of America 1991;88(12):5237-41.

223. Gross M, Kruisselbrink T, Anderson K, et al. Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev 1999;8(8):683-92.

224. Vatsis KP, Weber WW, Bell DA, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995;5(1):1-17.

225. Brockton N, Little J, Sharp L, Cotton SC. N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review. American Journal of Epidemiology 2000;151(9):846-61.

226. Lang NP, Chu DZ, Hunter CF, Kendall DC, Flammang TJ, Kadlubar FF. Role of aromatic amine acetyltransferase in human colorectal cancer. Archives of Surgery 1986;121(11):1259-61.

227. Ilett KF, David BM, Detchon P, Castleden WM, Kwa R. Acetylation phenotype in colorectal carcinoma. Cancer Res 1987;47(5):1466-9.

228. Roberts-Thomson IC, Ryan P, Khoo KK, Hart WJ, McMichael AJ, Butler RN. Diet, acetylator phenotype, and risk of colorectal neoplasia. Lancet 1996;347(9012):1372-4.

229. Ladero JM, Gonzalez JF, Benitez J, et al. Acetylator polymorphism in human colorectal carcinoma. Cancer Res 1991;51(8):2098-100.

230. Probst MR, Blum M, Fasshauer I, D'Orazio D, Meyer UA, Wild D. The role of the human acetylation polymorphism in the metabolic activation of the food carcinogen 2-amino-3-methylimidazo[4,5-f]quinoline (IQ). Carcinogenesis 1992;13(10):1713-7.

231. Liu Y, Levy GN. Activation of heterocyclic amines by combinations of prostaglandin H synthase-1 and -2 with N-acetyltransferase 1 and 2. Cancer Letters 1998;133(1):115-23.

232. DeMarini DM, Hastings SB, Brooks LR, et al. Pilot study of free and conjugated urinary mutagenicity during consumption of pan-fried meats: possible modulation by cruciferous vegetables, glutathione S-transferase-M1, and N-acetyltransferase-2. Mutation Research 1997;381(1):83-96.

233. Gil JP, Lechner MC. Increased frequency of wild-type arylamine-N-acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer. Carcinogenesis 1998;19(1):37-41.

234. Slattery ML, Potter JD, Samowitz W, Bigler J, Caan B, Leppert M. NAT2, GSTM-1, cigarette smoking, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 1998;7(12):1079-84.

235. Welfare MR, Cooper J, Bassendine MF, Daly AK. Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England. Carcinogenesis 1997;18(7):1351-4.

236. Kampman E, Slattery ML, Bigler J, et al. Meat consumption, genetic susceptibility, and colon cancer risk: a United States multicenter case-control study. Cancer Epidemiol Biomarkers Prev 1999;8(1):15-24.

237. Hubbard AL, Harrison DJ, Moyes C, et al. N-acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 8p deletions. Gut 1997;41(2):229-34.

238. Oda Y, Tanaka M, Nakanishi I. Relation between the occurrence of K-ras gene point mutations and genotypes of polymorphic N-acetyltransferase in human colorectal carcinomas. Carcinogenesis 1994;15(7):1365-9.

239. Potter JD, Bigler J, Fosdick L, et al. Colorectal adenomatous and hyperplastic polyps: smoking and N-acetyltransferase 2 polymorphisms. Cancer Epidemiology, Biomarkers & Prevention 1999;8(1):69-75.

240. Shibuta K, Nakashima T, Abe M, et al. Molecular genotyping for N-acetylation polymorphism in Japanese patients with colorectal cancer. Cancer 1994;74(12):3108-12.

241. Lee EJ, Zhao B, Seow-Choen F. Relationship between polymorphism of N-acetyltransferase gene and susceptibility to colorectal carcinoma in a Chinese population. Pharmacogenetics 1998;8(6):513-7.

242. Skog K, Steineck G, Augustsson K, Jagerstad M. Effect of cooking temperature on the formation of heterocyclic amines in fried meat products and pan residues. Carcinogenesis 1995;16(4):861-7.

243. Liu K, Slattery M, Jacobs D, Jr., et al. A study of the reliability and comparative validity of the cardia dietary history. Ethn Dis 1994;4(1):15-27.

244. Ishibe N, Sinha R, Hein DW, et al. Genetic polymorphisms in heterocyclic amine metabolism and risk of colorectal adenomas. Pharmacogenetics 2002;12(2):145-150.

245. Tiemersma EW, Kampman E, Bas Bueno de Mesquita H, et al. Meat consumption, cigarette smoking, and genetic susceptibility in the etiology of colorectal cancer: results from a Dutch prospective study. Cancer Causes Control 2002;13(4):383-93.

246. Welfare M, Monesola Adeokun A, Bassendine MF, Daly AK. Polymorphisms in GSTP1, GSTM1, and GSTT1 and susceptibility to colorectal cancer. Cancer Epidemiology, Biomarkers & Prevention 1999;8(4 Pt 1):289-92.

247. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer [see comments]. Lancet 1996;348(9040):1472-7.

248. Niv Y. Does a risk questionnaire add anything to a colorectal screening project? Report of a 3-year screening experience. J Clin Gastroenterol 1992;15(1):33-6.

249. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study [published erratum appears in N Engl J Med 1993 Aug 26;329(9):672] [see comments]. New England Journal of Medicine 1993;328(19):1365-71.

250. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test [see comments]. Lancet 1996;348(9040):1467-71.

251. Rozen P, Ron E, Fireman Z, et al. The relative value of fecal occult blood tests and flexible sigmoidoscopy in screening for large bowel neoplasia. Cancer 1987;60(10):2553-8.

252. Allison JE, Feldman R, Tekawa IS. Hemoccult screening in detecting colorectal neoplasm: sensitivity, specificity, and predictive value. Long-term follow-up in a large group practice setting [see comments]. Annals of Internal Medicine 1990;112(5):328-33.

253. Garvican L. Planning for a possible national colorectal cancer screening programme. J Med Screen 1998;5(4):187-94.

254. Elwood JM, Ali G, Schlup MM, et al. Flexible sigmoidoscopy or colonoscopy for colorectal screening: a randomized trial of performance and acceptability. Cancer Detect Prev 1995;19(4):337-47.

255. Hoff G, Vatn M, Gjone E, Larsen S, Sauar J. Epidemiology of polyps in the rectum and sigmoid colon. Design of a population screening study. Scandinavian Journal of Gastroenterology 1985;20(3):351-5.

256. Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992;256(5053):102-5.

257. Eguchi S, Kohara N, Komuta K, Kanematsu T. Mutations of the p53 gene in the stool of patients with resectable colorectal cancer. Cancer 1996;77(8 Suppl):1707-10.

258. Villa E, Dugani A, Rebecchi AM, et al. Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool [see comments]. Gastroenterology 1996;110(5):1346-53.

259. Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000;119(5):1219-27.

260. Gilbertsen VA, Nelms JM. The prevention of invasive cancer of the rectum. Cancer 1978;41(3):1137-9.

261. Friedman GD, Collen MF, Fireman BH. Multiphasic Health Checkup Evaluation: a 16-year follow-up. Journal of Chronic Diseases 1986;39(6):453-63.

262. Selby JV, Friedman GD, Quesenberry CP, Jr., Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer [see comments]. New England Journal of Medicine 1992;326(10):653-7.

263. Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM. Screening sigmoidoscopy and colorectal cancer mortality [see comments]. Journal of the National Cancer Institute 1992;84(20):1572-5.

264. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas [see comments]. New England Journal of Medicine 1992;326(10):658-62.

265. Atkin WS, Cuzick J. Screening for colorectal cancer [letter; comment]. Lancet 1993;341(8861):1667.

266. Taylor T, Williamson S, Wardle J, Borrill J, Sutton S, Atkin W. Acceptability of flexible sigmoidoscopy screening in older adults in the United Kingdom. J Med Screen 2000;7(1):38-45.

267. Atkin WS, Hart A, Edwards R, et al. Single blind, randomised trial of efficacy and acceptability of oral picolax versus self administered phosphate enema in bowel preparation for flexible sigmoidoscopy screening. Bmj 2000;320(7248):1504-8; discussion 1509.

268. Smith CA, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 1997;350(9078):630-3.

269. Atkin W. (Personal Communication) Adenoma rates between FlexiScope Centres, 2000.

270. Bingham SA, Welch AA, McTaggart A, et al. Nutritional methods in the European Prospective Investigation of Cancer in Norfolk. Public Health Nutr 2001;4(3):847-58.

271. Calvert C, Cade J, Barrett JH, Woodhouse A. Using cross-check questions to address the problem of mis-reporting of specific food groups on Food Frequency Questionnaires. UKWCS Steering Group. United Kingdom Women's Cohort Study Steering Group. Eur J Clin Nutr 1997;51(10):708-12.

272. Schaefer EJ, Augustin JL, Schaefer MM, et al. Lack of efficacy of a food-frequency questionnaire in assessing dietary macronutrient intakes in subjects consuming diets of known composition. Am J Clin Nutr 2000;71(3):746-51.

273. Abdel-Rahman SZ, El-Zein RA, Zwischenberger JB, Au WW. Association of the NAT1*10 genotype with increased chromosome aberrations and higher lung cancer risk in cigarette smokers. Mutation Research 1998;398(1-2):43-54.

274. Le Marchand L, Hankin JH, Wilkens LR, et al. Combined effects of well-done red meat, smoking, and rapid N- acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10(12):1259-66.

275. Day N, McKeown N, Wong M, Welch A, Bingham S. Epidemiological assessment of diet: a comparison of a 7-day diary with a food frequency questionnaire using urinary markers of nitrogen, potassium and sodium. Int J Epidemiol 2001;30(2):309-17.

276. Bingham SA. Dietary assessments in the European prospective study of diet and cancer (EPIC). Eur J Cancer Prev 1997;6(2):118-24.

277. Houlston RS, Tomlinson IP. Polymorphisms and colorectal tumor risk. Gastroenterology 2001;121(2):282-301.